Pellicelli, Adriano M <br/><br/>
Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late.  [electronic resource] 

 -  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver  Oct 2014 
 - 923-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1878-3562 
<br/><br/><label>Standard No.: </label>10.1016/j.dld.2014.06.004  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antiviral Agents--therapeutic use<br/>Carbamates<br/>Compassionate Use Trials<br/>Drug Administration Schedule<br/>Drug Therapy, Combination<br/>Female<br/>Follow-Up Studies<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Imidazoles--therapeutic use<br/>Liver Transplantation<br/>Male<br/>Middle Aged<br/>Prospective Studies<br/>Pyrrolidines<br/>Recurrence<br/>Severity of Illness Index<br/>Sofosbuvir<br/>Treatment Outcome<br/>Uridine Monophosphate--analogs & derivatives<br/>Valine--analogs & derivatives